- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review. (Pubmed Central) - Sep 21, 2024
In further experiments using animal models of nerve crush injury, specimens given GLP-1 agonists reported a significant increase in the rate and density of nerve regeneration compared to controls. Thus, GLP-1 agonists show promise as both prophylactic and symptomatic treatment for MS and may provide further utility in the treatment of other autoimmune, inflammatory, and neurodegenerative conditions.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, retatrutide (LY3437943) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
Journal: Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (Pubmed Central) - Sep 20, 2024
Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Byetta (exenatide) / AstraZeneca
Review, Journal: Endothelial Dysfunction in Obesity and Therapeutic Targets. (Pubmed Central) - Sep 20, 2024
Although endothelial dysfunction and oxidative stress are alleviated by either metformin or EMPA, currently used drugs to treat obesity-related diabetes neither possess the same anti-inflammatory potential nor simultaneously target endothelial cell dysfunction and obesity equally. While therapeutic interventions with glucagon-like peptide-1 (GLP-1) receptor
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Aphthasol (amlexanox) / Abeona Therap, Esteve, Lipaglyn (saroglitazar) / Zydus Lifesci
Review, Journal: Protein Kinases in Obesity, and the Kinase-Targeted Therapy. (Pubmed Central) - Sep 20, 2024
Co-treatment of antiobesity and antidiabetic herbal compound, berberine with antipsychotic drug olanzapine decreases the accumulation of triglyceride. While low-dose rapamycin, metformin, amlexanox, thiazolidinediones, and saroglitazar protect against insulin resistance, glucagon-like peptide-1 analog liraglutide inhibits palmitate-induced inflammation by suppressing mTOR complex 1 (mTORC1) activity and protects against lipotoxicity.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Trial completion: Liraglutide Effects on Epicardial Fat Inflammatory Genes (clinicaltrials.gov) - Sep 20, 2024
P4, N=38, Completed,
Most adverse effects were mild, and the IBD activity had no significant changes. Recruiting --> Completed
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Adlyxin (lixisenatide) / Sanofi
Retrospective data, Review, Journal: Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis. (Pubmed Central) - Sep 18, 2024
There is uncertain evidence on body fat and serious AEs, probably due to fewer studies and low incidence, respectively. Larger RCTs with head-to-head comparisons, pragmatic design, adiposity-related outcomes, and economic evaluation can further guide the use and choice of GLP-1RAs.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Weight Loss Pharmacotherapy: Current and Future Therapies. (Pubmed Central) - Sep 15, 2024
The patient experienced resolution of symptoms within days of stopping dulaglutide. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Retrospective data, Journal: One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. (Pubmed Central) - Sep 13, 2024
In this retrospective cohort study of 3389 patients with obesity, weight reduction at 1 year was associated with the medication's active agent, its dosage, treatment indication, persistent medication coverage, and patient sex. Future research should focus on identifying the reasons for discontinuation of medication use and interventions aimed at improving long-term persistent coverage.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal, Adverse events, Real-world evidence, Real-world: Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. (Pubmed Central) - Sep 12, 2024
GLP1-RAs exhibit higher reporting of suicide, hair loss, and aspiration events when compared to several other antidiabetic medications despite not meeting the criteria for positive signals yet. This warrants intensive monitoring and reporting.
- |||||||||| Review, Journal: Managing bile acid diarrhea: aspects of contention. (Pubmed Central) - Sep 12, 2024
They are relatively inexpensive, and better-quality data is now available for colesevelam...The GLP-1 receptor agonist, liraglutide, is also effective, although mechanisms of action and whether this effect is common to other class members is unclear...The role of dietary factors in symptom development is a major patient concern, needing more formal studies. To build on recent findings, bile acid diarrhea needs further investment into causes, diagnosis and therapy to guide present and future patient care.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Meridia (sibutramine) / AbbVie
Retrospective data, Journal: Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis. (Pubmed Central) - Sep 11, 2024
These results signify its viability as a favourable treatment option for managing PCOS symptoms in women living with obesity. Metformin 750 mg with lifestyle modification was the most effective treatment for AIWG, followed by topiramate 200 mg, metformin 750 mg, and topiramate 100 mg with moderate certainty of evidence.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
Review, Journal: Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity. (Pubmed Central) - Sep 10, 2024
However, further research is needed to elucidate long-term safety and efficacy outcomes and to address potential disparities in access to care. Overall, this review highlights the relevance and timeliness of incorporating GLP-1RAs into the comprehensive management of pediatric obesity.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Review, Journal: Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. (Pubmed Central) - Sep 8, 2024
The development of pre-procedural guidelines is currently compromised by the poor evidence base, particularly in relation to the effect of long-acting GLP-1RAs on gastric emptying. We suggest pre-procedural management pathways for individuals on GLP-1RA-based therapy and discuss priorities for future research.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice. (Pubmed Central) - Sep 3, 2024
The activity of LSGLP-1R neurons rapidly decreased during naturalistic feeding episodes, while synaptic inactivation of LSGLP-1R neurons diminished the anorexic effects triggered by liraglutide. Together, these findings offer critical insights into the functional role of LSGLP-1R neurons in the physiological regulation of energy homeostasis and delineate their instrumental role in mediating the pharmacological efficacy of liraglutide.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Retrospective data, Review, Journal: Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. (Pubmed Central) - Sep 2, 2024
Of the 11 studies, 2 reported the occurrence of adverse reactions, which were primarily gastrointestinal. Compared with placebo and other drugs (e.g., insulin), liraglutide may improve glucose metabolism, lipid and liver function parameters, and visceral and subcutaneous fat in patients with T2DM and NAFLD, thus constituting an effective treatment for these patients.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Retrospective data, Journal: Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations. (Pubmed Central) - Aug 27, 2024
Compared with placebo and other drugs (e.g., insulin), liraglutide may improve glucose metabolism, lipid and liver function parameters, and visceral and subcutaneous fat in patients with T2DM and NAFLD, thus constituting an effective treatment for these patients. No abstract available
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Glucagon-like peptide-1 receptor agonist, liraglutide, attenuates fentanyl seeking behavior and associated c-Fos and tyrosine hydroxylase activation patterns in rat brains (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_7636;
During the 90 min extinction test, all rats pretreated with saline exhibited high seeking for fentanyl and an increase in expression of c-Fos and TH in areas associated with reward and aversion; this seeking behavior, and brain activation, was blocked by treatment with the GLP-1RA. Together, these data show that fentanyl taking and seeking in the most vulnerable drive neuronal activity in substrates involved in drug need and in reward/seeking and that treatment with the satiety agent, liraglutide, reverses both drug-seeking behavior and the associated patterns of brain activation.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
Importance of GLP-1 receptor produced in the orexigenic AgRP/NPY neurons of the arcuate nucleus (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_6033;
Together, these data show that fentanyl taking and seeking in the most vulnerable drive neuronal activity in substrates involved in drug need and in reward/seeking and that treatment with the satiety agent, liraglutide, reverses both drug-seeking behavior and the associated patterns of brain activation. The GLP-1R agonist Exendin-4 (Ex-4, 1
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Anorectic treatments for obesity increase consumption of a high-fat diet during re-feeding in Sprague Dawley rats. (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_6023;
In this context, some pharmacological treatments have shown high effectiveness in reducing body weight, especially drugs with an anorectic effect, such as liraglutide and phentermine...However, they also induced an increase in the consumption of high-fat food after fasting, which could eventually lead to a rebound effect. Parameters in brain areas involved in feeding control must be evaluated to understand the underlying mechanism of this behavior.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Effects of Liraglutide on STZ-Treated Aged C57 Mice (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_3015;
Our findings suggest that LIR had only modest effects on the behavioral performance of the mice and this correlated with the changes observed in the biochemical profiles of the mice. These results suggest that the modest effects of LIR in the aged and STZ-treated C57 mice indicate that earlier interventions with LIR treatment might be needed in order to optimize its therapeutic effects.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. (Pubmed Central) - Aug 20, 2024
Significant disproportionality was detected only for semaglutide-associated suicidal ideation (ROR, 1.45; 95% CI, 1.18-1.77; IC, 0.53; 95% CI, 0.19-0.78), which remained significant in patients with coreported use of antidepressants (ROR, 4.45; 95% CI, 2.52-7.86; IC, 1.96; 95% CI, 0.98-2.63) and benzodiazepines (ROR, 4.07; 95% CI, 1.69-9.82; IC, 1.67; 95% CI, 0.11-2.65), when compared with dapagliflozin (ROR, 5.56; 95% CI, 3.23-9.60; IC, 0.70; 95% CI, 0.36-0.95), metformin (ROR, 3.86; 95% CI, 2.91-5.12; IC, 1.20; 95% CI, 0.94-1.53) and orlistat (ROR, 4.24; 95% CI, 2.69-6.69; IC, 0.70; 95% CI, 0.36-0.95). This study using the WHO database found a signal of semaglutide-associated suicidal ideation, which warrants urgent clarification.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Combination Therapy of Glucagon-Like-Peptide-1 Receptor Agonists and Endoscopic Gastric Plication in Obesity Population: A Meta-Analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_5384;
In the EGP+GLP-1 RAs group , the patients reached 20.05% [95% CI: 9.38-30.73] TBWL, 73.19% [95% CI: 19.86-126.53] EWL at the 6-month post-intervention, and 16.50% [95% CI: -4.46 to 37.46] TBWL at the 12-month post-intervention. In the EGP group, the patients reached 16.56% [95% CI: 9.28-23.85] TBWL, 57.40% [95% CI: 38.47-76.33] EWL at the 6-month post-intervention, and 13.49% [95% CI: -34.77 to 61.76] TBWL at the 12-month post-intervention.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Xenical (orlistat) / Roche, GSK
ESG Combined With Pharmacotherapy is Associated With Greater Patient Visit Compliance Compared to ESG Alone (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_4993;
Demographic data (ESG alone, ESG with pharmacotherapy) included: female gender (88%, 84%), average age in years at time of ESG (43, 43), pre-ESG weight in pounds (215, 216), and pre-ESG BMI (36.5, 36.3). Notably, the average number of follow-up visits per year was significantly higher for patients who underwent combined ESG and pharmacotherapy compared to ESG alone, attributable to a significant increase in the number of gastroenterology NP and especially MD visits per year.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Xenical (orlistat) / Roche, GSK
No Clinically Significant Change in FIB-4 Score With ESG or Combined Therapy With ESG and Pharmacotherapy (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_4992;
Demographic data (ESG alone, ESG with pharmacotherapy) included average age in years (42, 43), female gender (96%, 86%), pre-ESG weight in pounds (208, 214) and BMI (35.7, 36.8). There was no significant difference in pre-ESG or post-ESG FIB-4 scores between the 2 groups.
|
